Aditya Bardia, MD, MPH
Advertisement
Articles by Aditya Bardia, MD, MPH
TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study
ByAditya Bardia, MD, MPH,Virginia Kaklamani, MD, DSc,Joyce A. O’Shaughnessy,Peter Schmid, MD,J. Thaddeus Beck,,Michelino De Laurentiis,Guiseppe Curigliano,Hope S. Rugo, MD,Carlos Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Leo Viana Nicacio,Tomer Wasserman,Sara M. Tolaney, MD, MPH
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
Findings from DESTINY-Breast06 showed a PFS of 13.2 months for patients given T-DXd for HER2-low or ultralow breast cancer.
Aditya Bardia, MD, MPH, FASCO, spoke about how the FDA approval of T-DXd in HER2-low or ultralow breast cancer will allow for a broader treatment range.
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
ByFatima Cardoso,Joyce O’Shaughnessy, MD,Heather McArthur, MD, MPH,Peter Schmid, MD,Javier Cortés, MD,Nadia Harbeck, MD, PhD,Melinda L. Telli, MD,David W. Cescon,Peter A. Fasching,Zhimin Shao,Delphine Loirat,Yeon Hee Park,Manuel Gonzalez Fernandez,Gábor Rubovszky,Seock-Ah Im,Rina Hui,Toshimi Takano,Fabrice André,Hiroyuki Yasojima,Zhenzhen Liu,Yu Ding,Liyi Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia, MD, MPH
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH,Paul V. Plourde,David J. Portman,Senthil Damodaran
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
ByHope S. Rugo, MD,Aditya Bardia, MD, MPH,Komal Jhaveri,Seock-Ah Im,Senia Pernas,Michelino De Laurentiis,Shusen Wang,Noelia Martínez Jañez,Giuliano Borges,David W. Cescon,Masaya Hattori,Yen-Shen Lu,Erika P. Hamilton, MD,Qingyuan Zhang,Junji Tsurutani,Kevin Kalinsky, MD, MS,Lu Xu,Neelima Denduluri,Binghe Xu,Barbara Pistilli
Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.
Advertisement
Latest Updated Articles
Clinical Trial Data on Use of ctDNA AssaysPublished: August 10th 2022 | Updated:
- Impact of ctDNA on the Management of Breast Cancer
Published: August 18th 2022 | Updated:
Recap Evolving HER2+ Metastatic Breast Cancer LandscapePublished: December 31st 2021 | Updated:
Oncologists Reflect on Pandemic's Lasting Impact on Cancer CarePublished: March 10th 2025 | Updated:
Nuancing the Benefit of Circulating Tumor DNAPublished: August 10th 2022 | Updated:
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE TrialPublished: June 23rd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
Collagen Implant May Improve Local Control of Metastatic Brain Tumors
5
